Latest TXG news

3 Analysts, 3 Trades to Make Today

InvestorPlace · Tue, 22 Sep 2026 17:00:00 -0400

On any given day, there's a headline, a fear, or a worry screaming for your attention. We regularly cover those headlines here, doing our best to separate the signal from the noise so you can keep moving toward your financial goals.

Lunit Announces Collaboration with 10x Genomics to Integrate AI-Enabled Pathology Analysis with Spatial Molecular Data for Oncology Clinical Research

PRNewsWire · Thu, 10 Sep 2026 09:00:00 -0400

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?

Zacks Investment Research · Thu, 03 Sep 2026 14:56:11 -0400

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Benzinga · Tue, 01 Sep 2026 12:25:12 -0400

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences

Zacks Investment Research · Mon, 31 Aug 2026 14:16:05 -0400

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences

PRNewsWire · Fri, 28 Aug 2026 14:38:00 -0400

Jury finds Parse willfully infringed Scale Biosciences' patents and rejects Parse's invalidity challenge PLEASANTON, Calif., Aug. 28, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that a jury in the U.S. District Court for the District of Delaware found that Parse Biosciences, now a subsidiary of Qiagen (NYSE: QGEN), willfully infringed three patents exclusively licensed to Scale Biosciences, part of 10x Genomics since 2025.

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

Seeking Alpha · Thu, 20 Aug 2026 07:55:28 -0400

Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG's valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution.

Market information is provided for research and visualization and is not investment advice.